Ignite Creation Date:
2024-05-06 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05024058
Status:
TERMINATED
Last Update Posted:
2024-06-18
First Post:
2021-08-23
Brief Title:
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multi-center Randomized Double-blind Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab QGE031 in the Treatment of Chronic Inducible Urticaria CINDU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Status:
TERMINATED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Phase III PEARL studies CQGE031C2302 and CQGE031C2303 with ligelizumab met their primary endpoint of superiority vs placebo at Week 12 for treatment of CSU but not versus omalizumab Decision to discontinue was not based on safety concerns
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEARL-PROVOKE
Brief Summary:
This was a placebo controlled phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
Detailed Description:
There are currently no approved therapies for patients with CINDU who remain symptomatic despite treatment with H1-antihistamines The purpose of this study was to establish efficacy and safety of ligelizumab QGE031 over placebo in participants with chronic inducible urticaria CINDU who remain symptomatic despite treatment with H1 antihistamine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-003018-11 | EUDRACT_NUMBER | None | None |